State CIOs advocate for adherence to MITA standards

Maze - 49.10 Kb
The Medicaid Information Technology Architecture (MITA) framework is a way states can decouple legacy systems and break down existing silos in state government, according to the latest issue brief, “A Golden Opportunity for Medicaid IT Transformation: State CIOs and the MITA Framework,” released by the National Association of State Chief Information Officers (NASCIO).

NASCIO, an advocate for enterprise technologies, believes state adherence to the MITA 3.0 guidance set forth by the Centers for Medicare & Medicaid Services is imperative for increasing the agility and interoperability of the state Medicaid enterprise, according to a release.

“There are substantial fiscal incentives for states to meet the seven standards and conditions for enhanced federal funding, but the benefit of state adherence to the principles of MITA will also be advantageous to citizens, federal government and the vendor community,” said Doug Robinson, NASCIO executive director. “Budgets are tight and Medicaid expansion is going to be a major concern for the states. State CIOs recognize there needs to be an enterprise approach that focuses on re-use and adaptability of emerging technologies to find potential savings.”

The report is available at www.nascio.org/publications.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.